Literature DB >> 29416866

The evolution of fibrin-specific targeting strategies.

Victoria L Stefanelli1, Thomas H Barker1,2.   

Abstract

Fibrin-specific targeting capabilities have been highly sought for over 50 years due to their implications for bio-molecule delivery, diagnostics, and regenerative medicine. Yet only recently has our full knowledge of fibrin's complex polymerization dynamics and biological interactions begun to be fully exploited in pursuit of this goal. This highlight will discuss the range of rapidly changing strategies for specifically targeting fibrin over the precursor fibrinogen and the advantages and disadvantages of these approaches for various applications.

Entities:  

Year:  2015        PMID: 29416866      PMCID: PMC5798253          DOI: 10.1039/C4TB01769B

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  85 in total

1.  Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide.

Authors:  M L Thakur; V R Pallela; P M Consigny; P S Rao; D Vessileva-Belnikolovska; R Shi
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

2.  Biomimetic amplification of nanoparticle homing to tumors.

Authors:  Dmitri Simberg; Tasmia Duza; Ji Ho Park; Markus Essler; Jan Pilch; Lianglin Zhang; Austin M Derfus; Meng Yang; Robert M Hoffman; Sangeeta Bhatia; Michael J Sailor; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

3.  125-I-labelled fibrinogen test adapted for routine screening for deep-vein thrombosis.

Authors:  V V Kakkar; A N Nicolaides; J T Renney; J R Friend; M B Clarke
Journal:  Lancet       Date:  1970-03-14       Impact factor: 79.321

4.  The sequence A alpha-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies.

Authors:  W J Schielen; M Voskuilen; G I Tesser; W Nieuwenhuizen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

5.  Detection of experimental thrombi in rabbits with an 131I-labelled fibrin-specific monoclonal antibody.

Authors:  K Z Walker; L J Milner; G J Bautovich; P Borham; A K Wood; D B Rylatt; P Martin; P G Bundesen; G R Boniface
Journal:  Eur J Nucl Med       Date:  1990

6.  Development of human anti-murine antibody (HAMA) response in patients.

Authors:  J J Tjandra; L Ramadi; I F McKenzie
Journal:  Immunol Cell Biol       Date:  1990-12       Impact factor: 5.126

Review 7.  Radiolabeled peptides in the detection of deep venous thrombosis.

Authors:  R Taillefer
Journal:  Semin Nucl Med       Date:  2001-04       Impact factor: 4.446

8.  A fast-acting, modular-structured staphylokinase fusion with Kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy.

Authors:  Sau-Ching Wu; Francis J Castellino; Sui-Lam Wong
Journal:  J Biol Chem       Date:  2003-03-19       Impact factor: 5.157

9.  125I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients.

Authors:  A W Lensing; J Hirsh
Journal:  Thromb Haemost       Date:  1993-01-11       Impact factor: 5.249

10.  Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility.

Authors:  Josef Vymazal; Elmar Spuentrup; Gerardo Cardenas-Molina; Andrea J Wiethoff; Michael G Hartmann; Peter Caravan; Edward C Parsons
Journal:  Invest Radiol       Date:  2009-11       Impact factor: 6.016

View more
  5 in total

1.  What makes D-dimer assays suspicious-heterophilic antibodies?

Authors:  Ying Wu; Ying-Xiu Xiao; Teng-Yi Huang; Xian-Yan Zhang; Huan-Bing Zhou; Xue-Xuan Zhang; Ying-E Wu
Journal:  J Clin Lab Anal       Date:  2018-10-15       Impact factor: 2.352

2.  Modification of adipose mesenchymal stem cells-derived small extracellular vesicles with fibrin-targeting peptide CREKA for enhanced bone repair.

Authors:  Qi Wu; Xiaoling Fu; Xian Li; Jing Li; Weiju Han; Yingjun Wang
Journal:  Bioact Mater       Date:  2022-05-31

3.  Enhancing clot properties through fibrin-specific self-cross-linked PEG side-chain microgels.

Authors:  Nicole Welsch; Ashley C Brown; Thomas H Barker; L Andrew Lyon
Journal:  Colloids Surf B Biointerfaces       Date:  2018-03-02       Impact factor: 5.268

Review 4.  Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective.

Authors:  Fanny Risser; Ivan Urosev; Joanan López-Morales; Yang Sun; Michael A Nash
Journal:  Biophys Rev       Date:  2022-04-06

5.  Identification of and solution for false D-dimer results.

Authors:  Xian-Yan Zhang; Xue-Xuan Zhang; Jia-Long Xu; Teng-Yi Huang; Ying Wu; Ye-Ru Yang; Huan-Bin Zhou; Ying-E Wu
Journal:  J Clin Lab Anal       Date:  2020-01-22       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.